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Breast cancer is the most common malignancy in women, with an
incidence that varies between 40 and 90 per 100 000 (standardized
rate) worldwide. Breast cancer is the most frequent female tumour
in Italy, representing about 25% of all female tumours as reported
in Italian registries (Zanetti et al, 1997).
A positive family history is known to be a high risk factor for
developing the disease: 5–10% of all breast cancers arise in indi-
viduals carrying a germline mutation and are usually considered
hereditary forms (Claus et al, 1991). Two major breast cancer-
susceptibility genes, BRCA1 and BRCA2, have been cloned (Miki
et al, 1994; Wooster et al, 1995) and both are thought to account
for 30–60% of hereditary breast cancer (Serova et al, 1997; Szabo
et al, 1997; Vehmanen et al, 1997a, 1997b). However, large-scale
mutation analyses conducted in several populations suggest the
existence of additional breast cancer-susceptibility gene(s).
BRCA1 mutations are responsible for the majority of familial
breast cancer associated with ovarian carcinoma, for about 50% of
cases with breast cancer alone and for very few male breast cancer
cases (Easton et al, 1993; Stratton et al, 1994; Narod et al, 1995). It
has been estimated that women carrying a germline mutation in
BRCA1 have a risk ranging from 80 to 90% for developing breast
cancer and from 44 to 63% for developing ovarian cancer (Easton
et al, 1993, 1995; Ford et al, 1994; Miki et al, 1994; Wooster et al,
1994).  BRCA2 mutations account for a similar proportion of
inherited breast cancer and are frequently associated with male
breast cancer (Wooster et al, 1995). Breast cancer risk in females
carrying  BRCA2 mutations is calculated to be similar to that
conferred by BRCA1 mutations (Easton et al, 1993, 1997; Ford et
al, 1994; Miki et al, 1994; Wooster et al, 1994). BRCA1 and partic-
ularly BRCA2 families are often affected by other tumours such as
prostate, liver, pancreas, lung, stomach and colorectum (Wooster
et al, 1995; Gudmundsson et al, 1996; Phelan et al, 1996;
Thorlacius et al, 1996; Vehmanen et al, 1997b; Tonin et al, 1998).
Except for higher incidences of ovarian cancer in families with
mutations in a 3.3-kb region of exon 11 of BRCA2 (the so-called
ovarian cancer cluster region [OCCR]; Gayther et al, 1997), no
other significant association between genotype and phenotype was
described.  BRCA1 and  BRCA2 mutations are for the most part
frame-shifts due to small deletions leading to premature transla-
tion termination (Wooster et al, 1995; Phelan et al, 1996; Tavtigian
et al, 1996; Gayther et al, 1997).
Some of these mutations are prevalent in genetically homoge-
neous populations as a consequence of a founder effect. A single
BRCA2 mutation accounts for the majority of hereditary breast
cancer in Iceland (Gudmundsson et al, 1996; Thorlacius et al,
1996) and for 40% of male breast cancer cases (Johannesdottir et
al, 1996), whereas three different founder mutations (185delAG
and 5382insC in BRCA1, and 6174delT in BRCA2) have a high
frequency in Ashkenazi Jews (Roa et al, 1996). Although at
different rates, BRCA1 and BRCA2 founder mutations have been
detected in other genetically homogeneous populations, such as
the Finns (Vehmanen et al, 1997a) and the French-Canadians
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DOI: 10.1054/ bjoc.1999.0963, available online at http://www.idealibrary.com on (Tonin et al, 1998). In Sardinia, epidemiological data from the
Regional Tumor Registry (accounting for the northern part of the
island) indicate that breast carcinoma is the principal death-
causing malignancy, with an incidence of 93 per 100 000 inhabi-
tants (standardized rate) (Budroni et al, 1998). Sardinian
population is genetically separated from that of the rest of Italy as
well as from other European populations, due to strong genetic
drift. All the monogenic disorders analysed, such as thalassemia
(Pirastu et al, 1987), seem to be associated with a single founder
mutation throughout the island. Therefore, it seems possible that
such a founder effect could also be identified for a complex
disease like cancer. This can be done by tracing back the mutation
by linkage disequilibrium with genetic markers which give rise to
a shared haplotype among the patients. On this basis, we decided
to analyse the BRCA2 gene using the identity-by-descent method,
which allowed the identification of a mutation with founder effect
in Sardinian breast cancer families.
MATERIALS AND METHODS
Breast cancer patients
Collaborating physicians at both the Department of Medical
Oncology and the Institute of Histo-Pathology at Sassari
University collected seven Sardinian families. Family ascertain-
ment was carried out using the following criteria: (a) families with
at least two affected members in different generations (either a
first-degree relative or relative affected before age 50), or (b) fami-
lies with at least three affected members. Clinical information was
obtained from medical records.
Families were all apparently unrelated and originated from
different small villages located in the northern-central part of the
island; none of them presented cases of ovarian cancer. Three
families had other forms of cancer (Figure 1). No breast cancer
was detected in male members of the pedigrees. Blood samples
were collected from 17 affected (15 breast cancer, one prostate
cancer and one bladder cancer) and 89 unaffected members.
Twenty unrelated nuclear families, originating from the same
geographical area with no history of breast cancer, were used as
controls for the haplotype study.
Paraffin-embedded normal tissues were obtained from 270
breast cancer patients consecutively collected during 1997. No
additional selection criteria were used to enrol patients in the
screening; all cases were included regardless of age of onset.
Sardinian origin was ascertained in all cases through genealogical
studies. Informed consent was obtained from each family member
before drawing blood.
DNA analysis
DNA was isolated from blood samples using standard methods
(Sambrook et al, 1989). DNA extraction from paraffin-embedded
tissue was performed by a modification of the Jackson et al (1989)
procedure. Briefly, single 7- to 8-mm tissue sections, cut from
paraffin blocks, were stirred for 30 min with 1 ml of xylene in 1.5-
ml tubes and centrifuged. The pellet was washed with ethanol, air-
dried and resuspended in lysis solution (0.5% sodium dodecyl
sulphate (SDS), 0.5 mg ml–1 proteinase K in 13 TE buffer). After
incubation at 37°C overnight and inactivation of proteinase K for
15 min, DNA was extracted with 1 vol of phenol, phenol–chloro-
form and chloroform. The supernatant was precipitated at –20°C
overnight. The DNA was washed with 70% ethanol, air dried and
resuspended in 10 mM Tris–HCl pH 7.5, 0.1 mM EDTA.
Polymorphic microsatellite markers used for haplotype analysis
are linked to BRCA2 gene at 13q12–q13 as reported in published
genetic and physical maps: cen-D13S1246-D13S289-D13S260-
D13S1698-BRCA2-D13S1701-D13S171-D13S267-D13S263-tel
(Couch et al, 1996; Vehmanen et al, 1997a; Neuhausen et al, 1998;
Marshmed map at http://www.marshmed.org). Polymerase chain
reactions (PCR) were carried out as suggested in the Human
Genome Database. PCR products were end-labelled with g-32P-
dATP and electrophoresed on 6% acrylamide/7M urea sequenc-
ing gels. Alleles, visualized by X-ray autoradiography, were
numbered according to size for each microsatellite repeat marker.
BRCA2 sequence analysis
Nucleotide sequencing of the entire BRCA2 coding regions was
initially performed in two patients with an identical haplotype
belonging to two different families. DNA was amplified with
primers specific for BRCA2 exons (sequences and conditions are
reported in the Human Genome Database). PCR products were gel
purified using Qiaquick spin columns (Qiagen) and sequenced by
Thermo Sequenase 33P-labelled terminator cycle sequencing kit
(Amersham Pharmacia Biotech).
Mutation screening
A new set of primers (Fd, 5¢-GTGTAACACATTATTACAGTG-3¢
and Rv, 5¢-AATTCCTCCTGAATTTTAGTG-3¢) was generated in
order to bracket the region containing the mutation. Amplification
conditions were: 94°C for 5 min, 30 cycles of 94°C for 30 s, 53°C
for 30 s, 72°C for 1 min and 72°C for 10 min. Samples were elec-
trophoresed on a 6% denaturing polyacrylamide gel for 2 h and the
2-bp deletion mutation was visualized as the faster migrating frag-
ment after silver staining.
RESULTS
Among the seven unrelated Sardinian families, 106 members,
including 15 breast cancer cases, were genotyped with markers
flanking the BRCA2 locus at 13q12–q13. Pedigrees of all selected
families are shown in Figure 1. The haplotypes generated with
markers from D13S1246 to D13S1701 showed a pattern that was
constant within each family for all affected members, as indicated
in Figure 1. Four families shared the same haplotype in a 6.5 cM
region from D13S1246 to D13S267. The haplotype shared by
families 2 and 4 extended over a 15 cM interval reaching
D13S263, the most telomeric marker (Figure 1). Interestingly, this
haplotype was not detected in 80 control chromosomes except for
alleles 11 and 2 of D13S171 and D13S267, respectively, found to
be in linkage disequilibrium in the general Sardinian population
(data not shown and Figure 1).
Patients III:18 of family 2 and patient III:6 of family 4 were
affected by bladder and prostate cancer respectively. They shared
the common extended haplotype of breast cancer patients. DNA
samples from other family members with different tumours,
including prostate, bladder, colorectal, gastric and brain (Figure 1)
were unfortunately not available for analysis.
Two unrelated affected members carrying the common
extended haplotype (patient III:7 of family 1 and II:2 of family 2;
Figure 1) were chosen for direct sequencing of the BRCA2 coding
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(8765delAG), in both patients (Figure 2). This mutation is
predicted to produce a truncated protein at codon 2867. The
8765delAG mutation was found in the remaining patients of
family 2 (patients III:2 and III:19) and family 1 (patient III:11)
(Figure 1). Interestingly, in patient III:19 of family 1 (Figure 1),
who carries a different haplotype (Figure 1) this mutation was not
detected. After screening the other five families, patient III:5 of
family 6 and patients III:7, III:12 and III:6 (prostate cancer) of
family 4 as well as patient III:18 (bladder cancer) of family 2 were
found positive for the presence of 8765delAG mutation as
expected from the shared haplotype (Figure 1). Patients from 
families 3, 5 and 7 were negative for the 8765delAG mutation,
confirming the haplotype results. Altogether this mutation was
detected in four out of seven families (60%).
To investigate the frequency of the 8765delAG mutation, we
analysed 270 paraffin-embedded normal tissues from breast cancer
patients coming from the northern-central part of Sardinia. All
cases were collected regardless of family history and age of onset.
We found that five out of 270 patients (1.7%) carried this mutation
(Table 1).
DISCUSSION
Sardinia has a relatively small, isolated, and genetically homoge-
neous population with a high rate of inbreeding making it ideal for
genetic studies on either monogenic or multifactorial disorders.
Several founder effects have already been demonstrated for mono-
genic diseases in this population. Therefore it seemed possible that
founder mutations could also be detected in cancer patients.
Analysis of family pedigrees over several generations and use of
polymorphic markers may identify a common identical-by-descent
haplotype, in affected individuals. This strategy could help
restricting the number of cases for mutation screening, avoiding
extensive analysis principally when the candidate gene is as large
as BRCA2.
In the seven breast cancer families with multiple affected
members in different generations, selected for our study, clinical
phenotype, absence of ovarian cancer and late age-of-onset
suggested  BRCA2 as a candidate gene. Genotyping with markers
flanking the BRCA2 gene at 13q12–q13 locus identified a large
haplotype in four out of seven families, not found in control chro-
mosomes from the same geographical area. A few patients from
each family were additionally genotyped with markers closely
linked to the BRCA1 gene at 17q21. We found no differences in
haplotype frequency between patients and normal controls (data
not shown). Presence of a founder mutation in the BRCA2 gene
was confirmed by identification of a 2-bp (AG) deletion in exon
20. This mutation is located outside of the OCCR region of the
BRCA2 gene, in agreement with ovarian cancer absence in our
families. This AG deletion at nucleotide 8765 was already
described as a founder mutation in Yemenite-Jews families (Lerer
et al, 1998), as well as French-Canadian families (Phelan et al,
1996; Tonin et al, 1998). In order to understand if this mutation has
a common ancestral origin we carried out a haplotype analysis of
Sardinian and French-Canadian families (DNA samples of two
French-Canadian 8765delAG carriers were kindly provided by P
Tonin). This study showed that in the two populations the
8765delAG is associated to different haplotypes (data not shown).
These results support the hypothesis that the 8765delAG mutation
occurred at least twice in different populations because of its posi-
tion in an AG-rich sequence which may be a mutational hot-spot.
The 8765delAG mutation was present in all affected individuals
who shared the identical-by-descent haplotype. Unfortunately,
some family members were not evaluated for such mutation due to
individual refusal to undergo this analysis. Patient III:19 of family
1 and breast cancer patients from other families showing a
different haplotype (Figure 1) were found to be negative for the
8765delAG mutation. Family 1 strikingly shows that two sisters
(patients III:11 and III:19) do not have the same genotype: patient
III:11, who carries the 8765delAG mutation, seems to have
received it from the father’s side (because the same mutation is
present in family member III:7). For patient III:19, who does not
carry this mutation, we can hypothesize that she either received
another mutation from the mother’s side (in which breast cancer is
also present) or she is a phenocopy due to the high heterogenity of
the genetic and non-genetic factors causing the disease. Actually,
the young age of the third-generation relatives and missing geno-
type data on some family members (i.e. the affected maternal aunt)
are hindering clarification of this point.
As reported in Figure 1, two patients with other tumours
(bladder carcinoma for patient III:18 of family 2 and prostate
carcinoma for patient III:6 of family 4) shared the same haplotype
with the breast cancer patients. In these two cases, we also found
the 8765delAG mutation. The association of other tumours with
breast cancer is reported by several authors (Phelan et al, 1996;
Thorlacius et al, 1996; Serova et al, 1997; Tonin et al, 1998) and is
confirmed in our families. It would be interesting to carry out a
screening for this mutation in families with familial bladder and
prostate cancers.
The frequency of 8765delAG in Sardinia was subsequently 
verified by screening 270 breast cancer patients consecutively
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Table 1 Mutational screening of unselected breast cancer patients.
Patients positive to Additional cancer cases
Age No. of patients 8765delAG in positive families
(age at diagnosis)
≤ 40 42 1 (39) 5 breast (1 male), 1 lung
41–60 120 1 (45) 5 breast, 1 lung, 1 liver
1 (57) 1 breast, 1 lung, 1 colon
> 60 108 1 (69) 2 breast, 1 colon, 1 lung, 1 larynx
1 (80) 2 breast, 1 rectum
The 270 consecutively collected patients are grouped according to age at diagnosis. For the five positive cases we indicate the age of onset and the number
and types of cancer present in their families.556 M Pisano et al
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c o n t i n u e dcollected over a 1-year period, regardless of family history or age
of onset, from the central-northern part of the island. We found
five patients positive to the 8765delAG mutation with a frequency
of 1.7% in this group of unselected patients (see Table 1).
Preliminary results of a similar screening conducted in breast
cancer patients from the southern part of the island indicate that
8765delAG mutation is present at a lower frequency (1/208;
0.5%).
The discrepancy in the frequency of the 8765delAG mutation
between familial (60%) and unselected cases (1.7%) probably is
due to the selection criteria used. Families were selected on the
basis of the presence of several affected cases in different genera-
tions segregating a dominant trait with high penetrance. On the
contrary, the mutation screening was carried out in unselected
cases of which only 5–10% are expected to be familial (Claus et al,
1991). In addition, as already shown in several similar studies
carried out in different populations, only a small proportion of
familial cases are due to BRCA2 defects. As a confirmation of this,
we found that the five patients (unrelated to our cohort of families)
carrying the 8765delAG mutation, came from families with
multiple cases of breast cancer as well as other tumours in first-
and second-degree relatives (data not shown). These data again
support the value of screening for this mutation in Sardinia.
Searching for the 8765delAG mutation in these kind of families
would be important for the detection of asymptomatic carriers.
Additional studies on the three 8765delAG-negative families
could help identifying new BRCA2 mutations in our population.
Although described as a founder mutation in other populations
(Lerer et al, 1998; Tonin et al, 1998), the 8765delAG may be
considered the first BRCA2 founder in Italian breast cancer fami-
lies. Most Italian breast cancer cases are BRCA1-linked with a
high incidence of familial ovarian cancer and without any
evidence of a founder effect (De Benedetti et al, 1996; Montagna
et al, 1996). An intriguing hypothesis is that founder effects might
be detected in other Italian regions by selection of families coming
from small geographical areas showing genetic micro-homo-
geneity. Indeed, the approach used in our study clearly demon-
strates that in multifactorial diseases like cancer, founder effects
are likely to be detected when the population studied is relatively
small and genetically homogeneous. Identification of prevalent
mutations in such populations could represent an essential pre
requisite for a prevention programme based on DNA analysis.
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